Kiat Ruxrungtham

Division of Allergy and Clinical Immunology, Dept of Medicine, Chulalongkorn University, Thailand

Associate Professor of Medicine, Head, Division of Allergy and Clinical Immunology, Department of Medicine, Chulalongkorn University. Deputy Director of HIV-NAT (The HIV Netherlands, Australia, Thailand Research Collaboration), AIDS Research Center, Thai Red Cross Society, Bangkok, Thailand. Deputy Director (on Strategic Plan), the Health Research Science Institute (HRI), Chulalolongkorn University, Bangkok, Thailand.

Research activities: Basic Science:
1.R&D on Vaccine delivery systems: Liposome, microparticles, dendritic cell targeting
2. Humanized HIV-CpG DNA vaccine
3. Der p 1 Th1 epitope mapping in Thais and der p 1 DNA vaccine development
Clinical Sciences:
1. HIV Therapeutic and vaccine clinical trials
2. Asthma therapeutic clinical trials.

Professional organisations: Research forum co-ordinator, and member of The Allergy and Immunology Society, Thailand (AIST). Scientific committee and the member of The Royal College of Physician, Thailand (RCPT). Secretary, and member of the Thai AIDS Society (TAS).

Competing interests: Professor Ruxrungtham has received research grants, consultancy fees, honoraria, and/or travel grants from Hoffmann-LaRoche, Merck, Sharp and Dohme, Bristol-Myers-Squibb, Gilead, Abbott and TIBOTEC and/or Jessen-Cilag. He was also involved in darunavir-related clinical trials.

Any competing interests declared are displayed with individual evaluations.

Faculty Member: Infectious Diseases > HIV Infection & AIDS: Clinical (since 15 November 2005)

All recent recommendations

• 3.0
  Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa.
  Recommended by Kiat Ruxrungtham
  
• 3.5
  HLA-B*5701 screening for hypersensitivity to abacavir.
  Recommended by Anthony Harries, Kathryn Phillips, Lindy Fox, Nikhil Yawalkar, Kiat Ruxrungtham
  
• 3.0
  Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
  Recommended by Kiat Ruxrungtham
  
• 6.4
  Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
  Recommended by Paul Volberding, Kiat Ruxrungtham
  
• 3.0
  Prevalence of darunavir resistance-associated mutations: patterns of occurrence and association with past treatment.
  Recommended by Kiat Ruxrungtham
  
• 3.0
  Longitudinal analysis of clinical markers following antiretroviral therapy initiated during acute or early HIV type 1 infection.
  Recommended by Kiat Ruxrungtham
  
• 3.0
  Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients.
  Recommended by Kiat Ruxrungtham